Crinetics Pharmaceuticals to announce Q4 and full year 2025 financial results on February 26, 2026. Conference call scheduled.
Quiver AI Summary
Crinetics Pharmaceuticals, Inc. announced that it will release its fourth quarter and full year 2025 financial results on February 26, 2026, after the market closes. A conference call will take place that same day at 4:30 p.m. ET, where management will discuss the financial results and provide a business update. Participation details for the call include dialing in or accessing a live webcast on the company's website. Crinetics is focused on developing treatments for endocrine diseases and related tumors, with its lead product, PALSONIFY™, approved for treating acromegaly. The company has a robust pipeline of over ten programs targeting various endocrine conditions and tumors.
Potential Positives
- Crinetics Pharmaceuticals is set to report its fourth quarter and full year 2025 financial results, indicating transparency and accountability to investors by keeping them informed of its financial performance.
- The conference call provides an opportunity for management to offer a business update, potentially highlighting progress and future strategic directions, which can boost investor confidence.
- Crinetics’ lead product, PALSONIFY™, is the first oral treatment approved by the U.S. FDA for its indication, underscoring the company’s innovation and commitment to addressing unmet medical needs in endocrine diseases.
- The company's diverse pipeline of 10+ disclosed programs, including late-stage candidates, suggests a robust commitment to R&D and potential for future growth in various therapeutic areas.
Potential Negatives
- The press release does not provide any financial guidance or expectations for the upcoming results, which may raise concerns among investors about the company's performance and trajectory.
- There is no mention of upcoming product launches or significant milestones that could indicate positive progress, potentially reflecting a lack of short-term achievements.
- The statement highlights a deep pipeline but provides no specifics on trial progress or timelines, which may lead to doubts about the viability and advancement of their projects.
FAQ
When will Crinetics Pharmaceuticals announce its financial results?
Crinetics Pharmaceuticals will report its fourth quarter and full year 2025 financial results on February 26, 2026.
What time is the Crinetics conference call?
The conference call to discuss financial results will start at 4:30 p.m. ET on February 26, 2026.
How can I access the Crinetics conference call?
You can access the call via dial-in numbers or through the live webcast on Crinetics' website.
What is PALSONIFY™ and what does it treat?
PALSONIFY™ (paltusotine) is an oral treatment for adults with acromegaly who had an inadequate response to surgery.
What other conditions is Crinetics developing treatments for?
Crinetics is developing treatments for conditions such as congenital adrenal hyperplasia, Cushing’s syndrome, and various neuroendocrine tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRNX Insider Trading Activity
$CRNX insiders have traded $CRNX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $CRNX stock by insiders over the last 6 months:
- DANA PIZZUTI (Chief Med and Dev Officer) has made 0 purchases and 7 sales selling 56,492 shares for an estimated $1,910,298.
- MATTHEW K FUST sold 16,000 shares for an estimated $716,000
- RICHARD SCOTT STRUTHERS (President & CEO) sold 4,000 shares for an estimated $180,000
- ISABEL KALOFONOS (Chief Commercial Officer) sold 2,500 shares for an estimated $137,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRNX Hedge Fund Activity
We have seen 120 institutional investors add shares of $CRNX stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,574,683 shares (+44.3%) to their portfolio in Q3 2025, for an estimated $107,235,546
- FARALLON CAPITAL MANAGEMENT LLC added 1,124,000 shares (+24.2%) to their portfolio in Q3 2025, for an estimated $46,814,600
- STATE STREET CORP removed 1,016,599 shares (-31.5%) from their portfolio in Q3 2025, for an estimated $42,341,348
- JPMORGAN CHASE & CO added 926,765 shares (+279.2%) to their portfolio in Q3 2025, for an estimated $38,599,762
- VESTAL POINT CAPITAL, LP removed 750,000 shares (-50.0%) from their portfolio in Q3 2025, for an estimated $31,237,500
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 655,588 shares (-91.5%) from their portfolio in Q3 2025, for an estimated $27,305,240
- FRANKLIN RESOURCES INC removed 628,738 shares (-96.9%) from their portfolio in Q3 2025, for an estimated $26,186,937
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRNX Analyst Ratings
Wall Street analysts have issued reports on $CRNX in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 01/08/2026
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
- Oppenheimer issued a "Outperform" rating on 09/30/2025
- Leerink Partners issued a "Outperform" rating on 09/29/2025
- JMP Securities issued a "Market Outperform" rating on 09/26/2025
- Baird issued a "Outperform" rating on 09/26/2025
- JP Morgan issued a "Overweight" rating on 09/24/2025
To track analyst ratings and price targets for $CRNX, check out Quiver Quantitative's $CRNX forecast page.
$CRNX Price Targets
Multiple analysts have issued price targets for $CRNX recently. We have seen 8 analysts offer price targets for $CRNX in the last 6 months, with a median target of $83.5.
Here are some recent targets:
- Richard Law from Goldman Sachs set a target price of $67.0 on 01/12/2026
- Jonathan Wolleben from Citizens set a target price of $105.0 on 01/08/2026
- Jeffrey Hung from Morgan Stanley set a target price of $80.0 on 01/06/2026
- Leland Gershell from Oppenheimer set a target price of $87.0 on 09/30/2025
- Joseph Schwartz from Leerink Partners set a target price of $88.0 on 09/29/2025
- Jonathan Wolleben from JMP Securities set a target price of $143.0 on 09/26/2025
- Brian Skorney from Baird set a target price of $62.0 on 09/26/2025
Full Release
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, February 26 at 4:30 p.m. ET
| Domestic: | 1 833-470-1428 | |
| International: | 1 646-844-6383 | |
| Access Code: | 027322 | |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link ( HERE ) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com .
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
[email protected]
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
[email protected]
(858) 345-6075
